AI Article Synopsis
- - The study explores the complex molecular characteristics of adult soft tissue sarcomas with complex karyotypes to identify new therapeutic targets, addressing the challenges posed by their genomic diversity.
- - Genomic profiling revealed high mutation rates in genes like TP53, ATRX, and PTEN, and identified three groups of CKS based on copy number variations linked to CDK4 and RB1.
- - The findings suggest potential therapeutic strategies, particularly targeting pathways associated with PDGFR, and recommend considering targeted therapies or combinations before chemotherapy for treating these sarcomas.
Article Abstract
Background: Several studies have investigated the molecular drivers and therapeutic targets in adult soft tissue sarcomas. However, such studies are limited by the genomic heterogeneity and rarity of sarcomas, particularly in those with complex and unbalanced karyotypes. Additional biomarkers are needed across sarcoma types to improve therapeutic strategies. To investigate the molecular characteristics of complex karyotype sarcomas (CKSs) for therapeutic targets, we performed genomic profiling.
Results: The mutational landscape showed that TP53, ATRX, and PTEN genes were highly mutated. CKS samples were categorized into three groups based on copy number variations that were associated with CDK4 and RB1 signatures. Integrated analysis of genomic and transcriptomic data revealed several pathways related to PDGFR, which could be a strategic target for anti-sarcoma therapy.
Conclusions: This study provides a detailed molecular classification of CKSs and proposes several therapeutic targets. Targeted or combinational therapies for treating CKS should be considered before chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311917 | PMC |
| http://dx.doi.org/10.1186/s12881-018-0722-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!